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BRCA1-associated protein 1 (BAP1) is a deubiquitinase that is mutated in 10–15% of clear cell renal cell car
cinomas (ccRCC). Despite the association between BAP1 loss and poor clinical outcome, the critical tumor
suppressor function(s) of BAP1 in ccRCC remains unclear. Previously, we found that hypoxia-inducible factor 2α
(HIF2α) and BAP1 activate interferon-stimulated gene factor 3 (ISGF3), a transcription factor activated by type I
interferons and a tumor suppressor in ccRCC xenograft models. Here, we aimed to determine the mechanism(s)
through which HIF and BAP1 regulate ISGF3. We found that in ccRCC cells, loss of the von Hippel-Lindau tumor
suppressor (VHL) activated interferon beta (IFN-β) expression in a HIF2α-dependent manner. IFN-β was required
for ISGF3 activation and suppressed the growth of Ren-02 tumors in xenografts. BAP1 enhanced the expression of
IFN-β and stimulator of interferon genes (STING), both of which activate ISGF3. Both ISGF3 overexpression and
STING agonist treatment increased ISGF3 activity and suppressed BAP1-deficient tumor growth in Ren-02 xe
nografts. Our results indicate that BAP1 loss reduces type I interferon signaling, and reactivating this pathway
may be a novel therapeutic strategy for treating ccRCC.

1. Introduction
Kidney cancer is the sixth most prevalent cancer in men and the ninth
most prevalent cancer in women in the United States [1]. Clear cell renal
cell carcinoma (ccRCC), the major subtype of kidney cancer, accounts
for 70% of these cases. Clinically, great strides have been made in un
derstanding and treating ccRCC with recent advances in therapeutics,
including VEGFR tyrosine kinase inhibitors, immunotherapies targeting
PD-1/PD-L1 and CTLA-4, and a hypoxia-inducible factor 2α (HIF2α)
inhibitor [2–5]. Advanced ccRCC, however, remains a deadly disease,
and many patients do not benefit significantly from current therapies.
Loss of the von Hippel-Lindau tumor suppressor gene (VHL) is
characteristic of ccRCC. pVHL is a component of an E3 ubiquitin ligase
complex that targets the α subunits of HIF for oxygen-dependent
recognition and degradation [6,7]. VHL inactivation abolishes the
constitutive suppression of HIF, which drives the hypoxia response

transcriptional program that enhances cell growth, survival, and meta
bolism and is critical for ccRCC tumor growth [8–10]. Dysregulation of
the VHL-HIF axis alone, however, is insufficient for tumorigenesis.
Mutations in one or more secondary tumor suppressor genes, including
PBRM1, SETD2, and/or BAP1, promote the development of ccRCC
[11–14].
Germline mutations in the BRCA1-associated protein 1 gene (BAP1)
are associated with a tumor predisposition syndrome, where families
carrying this mutation are at increased risk of developing one or more
BAP1-associated cancers [15–17]. Somatic BAP1 mutations are
commonly found in several cancer types including uveal melanoma,
mesothelioma, cholangiocarcinoma, cutaneous melanoma, and ccRCC
[16,18]. Mutations in BAP1 are found in 10–15% of sporadic ccRCC
cases and are associated with poor patient prognosis [13,19–21]. At
present, no treatments specific to BAP1-deficient cancers have been
developed, although BAP1-deficient xenografted tumors are reported to
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be moderately sensitive to BET inhibitors [23]. Thus, a clearer under
standing of the molecular functions and mechanisms of tumor sup
pression by BAP1 is urgently needed to support drug development.
BAP1 is a deubiquitinase (DUB) that is primarily localized in the
nucleus. Both nuclear localization and DUB activity are important for its
tumor suppressor function, as demonstrated in a xenograft model using
BAP1− /− H226 lung cancer cells [24]. Cancer-associated BAP1 muta
tions abolish these features. BAP1 has been reported to have important
roles in various cellular processes, including histone modification [25,
26], transcriptional regulation [27,28], chromosome stability [29–31],
proliferation [32], DNA damage response [33–35], cell cycle progres
sion [36], ER stress [37], metabolism [38–40], apoptosis [41,42], fer
roptosis [43,44], cellular differentiation [45,46], and immune
regulation [47–50]. Interestingly, BAP1 functions appear to be cell typeand context-dependent. Few studies, however, have investigated the
specific molecular functions of BAP1 in ccRCC tumor suppression.
Previously, we demonstrated that HIF2α activates interferonstimulated gene factor 3 (ISGF3) to curb ccRCC progression, and many
secondary tumor suppressors, including BAP1, promote ISGF3 function
[51]. ISGF3 is a heterotrimeric transcription factor activated by type I
interferons (IFNs), including IFN-α and -β, which are produced in
response to pathogenic nucleic acids and mislocated cellular DNA.
Several cytoplasmic nucleic acid-sensing pathways, such as
cGAS-STING, converge on the activation of IRF3, a transcription factor
for type I IFN. Upon binding to the interferon α receptor (IFNAR),
IFN-α/β stimulates ISGF3, which is composed of phosphorylated STAT1
and STAT2 bound to IRF9. ISGF3 transcribes interferon-stimulated
genes that have antiviral, anti-proliferative, pro-apoptotic, and
pro-immunogenic functions [52]. Thus, the type I IFN pathway sup
presses tumor growth via both tumor cell-intrinsic and immune
cell-dependent mechanisms [53]. In this study, we investigated the
mechanism(s) by which the VHL-HIF axis and BAP1 regulate the ISGF3
pathway in ccRCC and defined the role of type I IFN in BAP1’s tumor
suppressor function.

to separate Petri dishes, minced, digested with 0.2% collagenase, and
placed in a 37 ◦ C incubator with 5% CO2 for 2 h. The cells were then
washed twice and seeded in BioLite 6-well Multidishes (130184; Thermo
Fisher) in RPMI medium containing 20% FBS. The derived primary
kidney cell cultures at passage 4 were seeded in multiple 6-well plates,
and the following day, cells were incubated with 1 μl Ad5CMVempty or
Ad5CMVCre virus (University of Iowa Viral Vector Core) at 5 × 1010
PFU/ml for 2 h at 37 ◦ C, with mixing performed every 10 min. Medium
containing the virus was then removed, the cells were washed, and 1.5
ml RPMI medium containing 20% FBS was added to each well, followed
by culturing in a 37 ◦ C incubator with 5% CO2 for 72 h. Cells were
harvested for immunoblot analysis.
2.3. Plasmids, mutagenesis, and subcloning
The BAP1 expression plasmid was generated by subcloning FlagBAP1 from pDEST-Flag-HA-BAP1 (gifted by Wade Harper, Addgene
plasmid 22539) into pLNCX-GFP (gifted by Wei Xu, University of
Wisconsin-Madison). The QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies, 200521-5, Santa Clara, CA, USA) was used to
generate mutations in BAP1. The pLNCX-IRF9-STAT2C (9-2C) plasmid
was generated by subcloning IRF9-STAT2C from pCDNA3-IRF9-STAT2C
(gifted by Curt Horvath, Addgene plasmid 37544) into pLNCX-GFP. All
primers used are listed in Supplementary Table I. All plasmids were
sequenced before use. The pBabe-EV and -VHL plasmids were gifted by
William Kaelin, Jr. pLKO shRNA constructs were obtained as bacterial
stocks from Millipore Sigma (Burlington, MA, USA), and the sequences
are listed in Supplementary Table II.
2.4. Western blotting
Cells were washed with PBS, scraped on ice, and resuspended in EBC
buffer (120 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% NP-40) or 1% SDS
containing protease and phosphatase inhibitors (Thermo Fisher, A32963
and 78420). SDS lysates were sonicated at 20 A for 3 × 15 s. For frac
tionation experiments, cells were resuspended in hypotonic buffer (10
mM KCl, 10 mM Tris-HCl pH 8.0, 1.5 mM MgCl2) to collect the cyto
plasmic fraction followed by 1% SDS with sonication to obtain the nu
clear fraction. Samples were boiled for 10 min in 5X loading buffer.
Proteins were resolved by SDS-PAGE and immunoblotted with the
indicated antibodies. Following standard western blotting procedures,
blots were developed using Immobilon Western Chemiluminescent HRP
substrates (Millipore Sigma, WBKLS0500) and imaged on an Image
Quant LAS 4000 (GE Healthcare Life Sciences, Marlborough, MA, USA).
For re-probing, the blots were stripped with Restore Western Blot
Stripping Buffer (Thermo Fisher, 21063) following the manufacturer’s
protocol. The antibodies and dilutions used are listed in Table 1.
Quantification was performed using ImageJ software. Values indicate
band intensity relative to the loading control and control samples.

2. Materials and methods
2.1. Cell culture and stable cell line generation
Cell lines were maintained in Gibco glutamine-containing DMEM
(Thermo Fisher, 11995-065, Waltham, MA, USA) supplemented with
10% fetal bovine serum (R&D Systems, S11150, Minneapolis, MN, USA)
and 1% penicillin and streptomycin (Thermo Fisher, 15140-122). Cells
were cultured at 37 ◦ C in incubators with 5% CO2. 786-O cells were
purchased from ATCC (CRL-1932, Manassas, VA, USA). UMRC2 and
UMRC6 cells were gifted by Qing Zhang (University of Texas South
western). Ren-02 cells were gifted by Daniel Lindner (Cleveland Clinic).
HEK293T and Phoenix cells were gifted by William Kaelin, Jr. (Dana
Farber Cancer Institute).
For the knockdown studies, lentiviruses were generated using
HEK293T cells. Briefly, 2 μg ΔR8.2 packaging plasmid, 200 ng VSV-G
envelope plasmid, and 2–4 μg pLKO shRNA plasmid were transfected
using Lipofectamine 2000. Virus-containing medium and 8 μg/ml pol
ybrene were used to infect the target cells. Cells were selected with 2.0
μg/ml puromycin for 4–7 d, and stable knockdown cells were main
tained in medium containing 0.5–2.0 μg/ml puromycin. For expression
studies, retroviruses were generated by transfecting Phoenix cells with
2–4 μg of pLNCX plasmid and Lipofectamine 2000. Target cells were
infected with virus and polybrene and selected with 1.0 mg/ml G418 for
7–14 d.

2.5. Quantitative PCR
Total RNA was extracted from cells using the RNeasy Plus Mini Kit
with QIAshredder columns (Qiagen, 74136 and 79654, Hilden, Ger
many), according to the manufacturer’s protocol. Reverse transcription
was performed with 0.5–2.5 μg RNA using the First Strand cDNA Syn
thesis Kit (Origene, NP100042, Rockville, MD, USA), RevertAid First
Strand cDNA Synthesis Kit (Thermo Fisher, K1622), or Invitrogen Su
perScript IV VILO Master Mix with ezDNase Enzyme (Thermo Fisher,
11766050) following the manufacturer’s protocol. Real-time PCR was
performed using Power Track SYBR Green Master Mix (Thermo Fisher,
A46113) on a StepOnePlus Real-Time PCR System or QuantStudio 3
Real-Time PCR System (Applied Biosystems). Cycling conditions were as
follows: initial denaturation at 95 ◦ C for 10 min, denaturation at 95 ◦ C
for 15 s and annealing at 60 ◦ C for 1 min (40 cycles) followed by a melt
curve. The primers used are listed in Supplementary Table III.

2.2. Generation of Bap1 knockout mouse kidney cells
Primary normal kidney cells were isolated from individual condi
tional knockout Bap1fl/fl and wild-type FVB littermates sacrificed at
10–12 weeks of age. The kidneys were excised, individually transferred
2
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calculated using equation V=(W2 × L)/2.

Table 1
Antibodies used in this study.
Antibody

Catalog number

Company

Dilution

BAP1
BAP1
PLSCR1
Vinculin
β-actin
VHL
STAT1
p-STAT1 (Y701)
p-STAT2 (Y690)
IRF9
RIG-I
MDA5
OAS1
STING
p-STING (S366)
p-IRF3 (S386)
IRF3
p-TBK1 (S172)
TBK1
cGAS
Lamin A/C
H2A
Ubiquityl-H2A (K119)
α-tubulin
MX1
STAT2
HIF2α
GLUT-1
anti-mouse IgG
anti-rabbit IgG
anti-goat IgG

sc-28236
sc-28383
sc-59645
sc-73614
sc-8432
2738
9172S
9171L
88410
76684S
3743S
5321S
14498S
13647S
50707S
37829
11904S
5483
3504
15102
2032
2578S
8240S
2144
AF7946
A303-512-A
A700-003
NB300-666
62–6520
31460
HAF109

Santa Cruz Biotechnology

1:1000
1:200

Cell Signaling Technology

1:1000

R&D Systems
Bethyl Laboratories

1:2000
1:1000
1:1000

Novus Biologicals
Invitrogen

1:2000
1:5000

R&D Systems

1:1000

2.9. Immunohistochemistry
Xenografted tumors were formalin-fixed and embedded in paraffin,
and 4-μM slides were deparaffinized using a Shandon Varistain Gemini
ES autostainer. Antigen retrieval was performed on slides using citrate
buffer (pH 6.0) at 98 ◦ C for 20 min in a DAKO PT Link apparatus
(Agilent). Immunostaining was performed using an IntelliPATH FLX
Autostainer (Biocare Medical, Pacheco, CA, USA) with the following
antibodies at the indicated dilutions: Ki67 (Abcam, ab16667, 1:200),
cleaved Caspase 3 (Cell Signaling Technology, 9661, 1:500), CD45 (BD
Pharmingen, 550539, 1:200), and CD31 (Santa Cruz, sc-1506, 1:500).
Biotinylated secondary antibodies against rabbit or rat (Vector Labora
tories, BA-1000 and BA-4001, Burlingame, CA, USA) and ABC-HRP
complexes (PK6100) were used, and the signals were developed using
DAB substrate (DAKO, K3468). Following washing, the slides were
counterstained with hematoxylin, dehydrated, cleared, and a coverslip
was placed.
2.9.1. Analysis of human ccRCC tissue microarray
A tissue microarray (TMA) was previously generated from 160
ccRCC patients at Fox Chase Cancer Center [54]. A total of 40 tumors per
stage were biopsied, and in most cases, 4 samples per tumor were ob
tained with informed consent. Immunohistochemistry was performed
for STING (Proteintech, 19851-1-AP, Rosemont, IL, 1:4000) and scored
by a pathologist. In the cancer cells and stroma, 0–10% positive staining
= 0, 11–50% positive = 1, and >51% positive = 2. Analysis of BAP1 IHC
staining in cancer cells was previously performed [51], and 0–10%
positive nuclear staining = 0 and > 11% positive nuclear staining = 1.
Logistic regression within a generalized estimating equations (GEE)
framework was used to evaluate the association between BAP1 IHC loss
and STING-cancer loss, or BAP1 IHC loss and STING-stromal loss while
accounting for correlation among multiple samples from the same pa
tient. The odds ratio for having a 0 in STING comparing BAP1 IHC 0 to
BAP1 IHC non-zero was calculated along with a 95% confidence inter
val, and a p-value was calculated to test the null hypothesis that OR = 1
(no association).

2.6. Cell proliferation assays
Cell proliferation was measured using the Cell Proliferation Kit II
(XTT) (Millipore Sigma, 11465015001), with slight modifications to the
manufacturer’s protocol. Briefly, 6.0 × 103 cells were seeded into 24well plates, and the XTT-labeling reagent and electron coupling re
agent (50:1) were added at the indicated time points in duplicate. After
incubation for 4 h, the absorbance was measured at 450 nm wavelength
on a Biotek Synergy microplate reader with background subtraction.

2.10. Statistical analyses

2.7. In vitro drug treatments
Cells were seeded to the desired confluency and treated the following
day with vehicle or the indicated treatment for 24 h. H-151 was pur
chased from Selleck Chemicals (S6652, Houston, TX, USA), IFN-β from
R&D Systems (8499-IF, Minneapolis, MN, USA), and diABZI from Med
Chem Express (2138299-34-8, Monmouth Junction, NJ, USA).

Data are reported as the mean ± SEM. Comparisons between con
ditions were performed using a two-tailed Student’s t-test. Statistical
significance was set at p < 0.05 and is denoted in the figures as follows:
*, p < 0.05; **, p < 0.01; and ***, p < 0.001. In vitro experiments were
performed a minimum of two times, and ≥10 mice were used for each in
vivo experiment. Significant outliers were removed using Grubb’s test
for qPCR data.

2.8. Mouse experiments

3. Results

Animal experiments were conducted under protocol 01462 approved
by the Institutional Animal Care and Use Committee of Thomas Jeffer
son University. Four-week-old male nude mice were purchased from
Charles River. For xenograft experiments, 1 × 107 Ren-02 cells
expressing the indicated plasmids in PBS or 1:1 PBS:Matrigel (Corning
Life Sciences, 354234, Tewksbury, MA, USA) were injected subcutane
ously into either flank of each mouse. Mice were sacrificed when tumors
reached the endpoint size or when they displayed signs of distress, and
tumors were dissected and weighed.
For the drug treatment experiment, 1 × 107 Ren-02 shBAP1-74 cells
were subcutaneously implanted into the right flank of nude mice. After
the tumors were established, the mice were treated with vehicle (40%
PEG-400, 0.9% NaCl, 10% DMSO, filtered) or 3 mg/kg diABZI (Med
Chem Express) via intraperitoneal injection every 3–4 d. Tumor size was
monitored over the course of treatment using a caliper. Volume was

3.1. VHL and HIF2α regulate IFN-β expression in ccRCC cells
Previously, we showed that VHL loss elevated the type I IFN signa
ture in ccRCC cells in a HIF2α-dependent manner; thus, we sought to
determine the cause of ISGF3 activation in this context. We hypothe
sized that canonical type I IFN signaling is regulated by the VHL-HIF
axis. First, to confirm the effect of VHL on ISGF3, VHL was reexpressed in VHL− /− 786-O and Ren-02 ccRCC cells, and ISGF3 down
stream target expression was investigated using western blotting. VHL
re-expression caused marked reductions in the protein levels of HIF2α,
its direct substrate, and ISGF3 transcriptional targets IRF9, OAS1, and
PLSCR1 in Ren-02 cells (Fig. 1A). Similar reductions in HIF2α and ISGF3
target levels were observed in 786-O cells (Fig. 1B). To investigate
whether VHL status affects the production of cytokines that activate
ISGF3, the expression of the major type I IFNs, IFN-α/β, was measured
3
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Fig. 1. VHL and HIF2α regulate IFN-β expression in ccRCC cells. (A) SDS-solubilized whole cell lysates of Ren-02 cells (n = 2) expressing an empty vector (EV) or
VHL construct and blotted with the indicated antibodies. (B) SDS-solubilized whole cell lysates of 786-0 cells (n = 3) expressing an empty vector (EV) or VHL
construct and blotted with the indicated antibodies. (C) RT-qPCR measurement of IFNB1 (n = 3) and IFNA (n = 4) gene expression in Ren-02 cells expressing an
empty vector (EV) or VHL construct. As IFN-α is transcribed from 13 distinct genes, the IFNA qPCR primers were designed to detect a region common to all IFN-α
transcripts. (D) RT-qPCR measurement of IFNB1 (n = 5) and IFNA (n = 6) gene expression in 786-O cells expressing an empty vector (EV) or VHL construct. (G) SDSsolubilized whole cell lysates of Ren-02 cells (n = 2) expressing control (SCR, scrambled) or HIF2α shRNAs and blotted with the indicated antibodies. (H) RT-qPCR
measurement of EPAS1 (HIF2α) transcripts in Ren-02 cells (n = 5) expressing the indicated shRNAs. (I) SDS-solubilized whole cell lysates of 786-O cells (n = 2)
expressing control or HIF2α shRNAs and blotted with the indicated antibodies. (J) RT-qPCR measurement of EPAS1 (HIF2α) transcripts in 786-O cells (n = 3)
expressing the indicated shRNAs.
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by real-time PCR. In Ren-02 cells, VHL re-expression markedly reduced
the transcript levels of IFNB1 but not IFNA (Fig. 1C). Similar results were
observed in 786-O cells (Fig. 1D).
To examine whether changes in IFN expression were caused by HIF
following VHL loss, two shRNAs were used to suppress HIF2α expression
in Ren-02 and 786-O cells. Suppression of HIF2α was confirmed by
western blot analysis of HIF2α and GLUT-1, a major HIF target gene, as
well as by real-time PCR analysis of EPAS1 (the gene encoding HIF2α).
In Ren-02, both HIF2α and GLUT-1 proteins were markedly diminished

by the shRNAs (Fig. 1E), and EPAS1 transcripts were reduced compared
to those in the control (Fig. 1F). In 786-O cells, HIF2α and GLUT-1
proteins were also markedly lower (Fig. 1G), and EPAS1 transcripts
were decreased in the knockdowns compared to those in the control
(Fig. 1H). Suppression of HIF2α reduced the expression of IFNB1 in Ren02 cells without significantly altering IFNA expression (Fig. 1I). Similar
results were observed in 786-O cells (Fig. 1J). This suggests that in
ccRCC cells, VHL and HIF2α both regulate IFNB1 expression.

Fig. 2. IFN-β activates ISGF3 and suppresses tumor growth in ccRCC. (A) RT-qPCR measurement of IFNB1 expression in Ren-02 cells (n = 5) expressing SCR or
IFNB1 shRNAs. (B) RT-qPCR measurement of ISGF3 target gene expression in Ren-02 cells (n = 5, 4, 4) expressing SCR or IFNB1 shRNAs. (C) RT-qPCR measurement
of IFNB1 expression in 786-O cells (n = 4) expressing SCR or IFNB1 shRNAs. (D) RT-qPCR measurement of ISGF3 target gene expression in 786-O cells (n = 5, 5, 3)
expressing SCR or IFNB1 shRNAs. (E) SDS-solubilized whole cell lysates of Ren-02 cells (n = 2) expressing the indicated shRNAs and blotted with the indicated
antibodies. (F) SDS-solubilized whole cell lysates of 786-O cells (n = 3) expressing the indicated shRNAs and blotted with the indicated antibodies. (G) Images of
athymic nude mice (n = 6) injected with Ren-02 cells expressing control (SCR) or IFNB1 shRNA, with xenografted tumors below. (H) Quantification of tumor
weights. Tumors from individual mice are connected by a line. The difference in tumor weights was calculated and compared using the two-tailed Student’s t-test. (I)
Graph of relative cell proliferation in the indicated cell lines measured via XTT assay (n = 3).
5
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ccRCC cells and

Next, we examined whether IFN-β caused ISGF3 activation in VHL−

ccRCC cells. IFNB1 was suppressed by two shRNA constructs in Ren-02
and 786-O cells, and knockdown was confirmed by real-time PCR. IFNB1
transcripts were significantly reduced in Ren-02 cells (Fig. 2A) and
caused dramatic reductions in the expression of ISGF3 target genes

−

/

Fig. 3. BAP1 promotes ISGF3 activity in a deubiquitinase-dependent manner. (A) SDS-solubilized whole cell lysates of UMRC6 cells expressing control (GFP),
BAP1-WT, or BAP1-C91G constructs and blotted with the indicated antibodies (left). Quantification of monoubiquitinated H2A/total H2A protein levels (n = 6) in
UMRC6 cells expressing the indicated constructs (right). (B) SDS-solubilized whole cell lysates of UMRC2 cells expressing control (GFP), BAP1-WT, or BAP1-C91G
constructs and blotted with the indicated antibodies (left). Quantification of monoubiquitinated H2A/total H2A protein levels (n = 6) in UMRC2 cells expressing the
indicated constructs (right). (C) SDS-solubilized whole cell lysates of UMRC6 cells (n = 7) expressing the indicated constructs and blotted with the indicated an
tibodies. (D) SDS-solubilized whole cell lysates of UMRC2 cells (n = 7) expressing the indicated constructs and blotted with the indicated antibodies. (E) SDSsolubilized whole cell lysates of Ren-02 cells (n = 3) expressing the indicated constructs and blotted with the indicated antibodies.
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OAS1, OAS2, and IFI44L (Fig. 2B). Similar results were observed in 786O cells, where IFNB1 suppression reduced its transcript levels (Fig. 2C)
and those of ISGF3 targets OAS1, IFI44L, and IFI6 (Fig. 2D). Addition
ally, IFNB1 knockdown was associated with reduced STAT1 and STAT2
phosphorylation at residues Y701 and Y690, respectively, as well as
decreased protein levels of several other ISGF3 targets including MDA5,
RIG-I, PLSCR1, MX1, and OAS1 in these cell lines (Fig. 2E and F). This
suggests that IFN-β is largely responsible for enhanced ISGF3 activity in
VHL− /− ccRCC cells.
Next, the effect of IFNB1 knockdown on tumor growth was investi
gated using mouse xenograft assays. Interestingly, tumors were only
generated by Ren-02 shIFNB1-01 cells in six of the ten nude mice in the
experiment, but not by the control cells (Fig. 2G and H). The suppression
of IFNB1 did not alter cell proliferation in vitro (Fig. 2I). These results
suggest that IFN-β is a tumor suppressor in ccRCC cells.

dependent manner.
Although BAP1 upregulates IFN-β, an activator of ISGF3, it is not
known whether BAP1’s regulation of ISGF3 is predominantly mediated
by IFN-β. Thus, IFNB1 was suppressed by shRNAs in UMRC6 cells
expressing GFP or BAP1 (Fig. 4G). In the BAP1− /− GFP cells, IFNB1
knockdown caused a modest decrease in the expression of ISGF3 target
genes OAS2, EPSTI1, and IFI44L (Fig. 4H–J, lanes 1–3), as well as MDA5,
RIG-I, and OAS1 (Fig. 4K, lanes 1–3). BAP1 re-expression activated
ISGF3 target expression, as expected, and this effect was abolished by
further suppression of IFNB1 (Fig. 4H–K, lanes 4–6). IFN-β treatment
reversed the effect of IFNB1 knockdown on ISGF3 target expression in
both Ren-02 and UMRC6 cells, showing this is an on-target effect of the
shRNA (Data in Brief Fig. 2). Further, suppression of IFNAR1, a
component of the type I IFN receptor, phenocopied IFNB1 loss in UMRC6
BAP1-expressing cells (Data in Brief Fig. 3). Interestingly, suppression of
IFNB1 and IFNAR1 increased the protein levels of exogenous BAP1
(Fig. 4H–K, lanes 4–6 and Data in Brief Fig. 3A), though the reason for
this is unknown. It is possible that IFN regulates the translational effi
ciency and/or protein stability of BAP1. To confirm that IFN-β secreted
by the cells was responsible for ISGF3 target activation, Ren-02 and
UMRC6 BAP1-expressing cells were treated with an IFN-β blocking
antibody, which reduced ISGF3 target transcript levels in a dosedependent manner (Data in Brief Fig. 4). These results support the hy
pothesis that the BAP1-dependent upregulation of ISGF3 is mediated by
secreted IFN-β.

3.3. BAP1 promotes ISGF3 activity in a deubiquitinase-dependent manner
While we previously described the involvement of BAP1 in ISGF3
regulation, we had not yet investigated the mechanism involved. To this
end, BAP1 expression and DUB activity were manipulated in UMRC6
(BAP1− /− ), UMRC2 (BAP1− /− ), and Ren-02 (BAP1+) ccRCC cell lines.
GFP, BAP1-WT (wild-type), and BAP1-C91G, a ccRCC-derived mutation
at the residue critical for DUB activity, were re-expressed in the BAP1− /−
cell lines. Expression of BAP1-WT, but not BAP1-C91G, reduced mono
ubiquitination at K119 of histone H2A, a well-defined target of BAP1, in
both UMRC6 (Fig. 3A) and UMRC2 cells (Fig. 3B). BAP1-WT also
enhanced the phosphorylation of STAT1 and STAT2 as well as protein
levels of many downstream targets of ISGF3, including MDA5, RIG-I,
OAS1, and PLSCR1, in UMRC6 cells (Fig. 3C, lanes 1–2). The C91G
mutant did not promote ISGF3 phosphorylation or transcriptional ac
tivity (Fig. 3C, lane 3). Similar results were observed in UMRC2 cells,
although interestingly, BAP1 appeared to reduce STAT1 phosphoryla
tion in this cell line (Fig. 3D). The stimulation of ISGF3 targets by BAP1
was dependent on ISGF3 activity, as IRF9 knockdown abolished BAP1mediated upregulation of the targets in UMRC6 cells (Data in Brief
Fig. 1A). Further, treatment with ruxolitinib, a JAK1/2 inhibitor, abol
ished the phosphorylation of STAT1 and STAT2 caused by BAP1
expression in UMRC6 cells (Data in Brief Fig. 1B).
In Ren-02 cells, BAP1 status was first verified by evaluating H2A
ubiquitination levels upon BAP1 knockdown or knockout. Suppression
of BAP1 by both methods increased H2A K119 ubiquitination, sug
gesting BAP1 retains DUB activity in this cell line (Supplementary
Figs. 1A–B). Additionally, the BAP1 mRNA product was reverse tran
scribed and sequenced, revealing BAP1 is indeed WT in Ren-02 cells
(Supplementary Figs. 1C–D). BAP1 suppression by shRNA resulted in
reduced phosphorylation of STAT2 and decreased expression of ISGF3
targets (Fig. 3E, lanes 1–2). Re-expression of shRNA-resistant BAP1-WT
(BAP1*) increased STAT2 phosphorylation and ISGF3 target gene
expression in the knockdown cells, while shRNA-resistant C91G
(C91G*) did not restore ISGF3 pathway activation to the same extent
(Fig. 3E, lanes 3–4). Together, this suggests that the C91G mutation
abolishes BAP1 DUB activity and firmly links BAP1’s regulation of ISGF3
to its deubiquitinase function.

3.5. BAP1 stimulates ISGF3 activity through STING
Because the cGAS-STING-IRF3 pathway is a major stimulator of IFNβ production, we investigated whether BAP1 regulates this upstream
event in this pathway. BAP1 re-expression in UMRC6 cells dramatically
increased STING protein levels, as well as STING phosphorylation at
S366 and IRF3 phosphorylation at S386 (Fig. 5A, lanes 1–2). Despite
being expressed at a level similar to BAP1-WT, BAP1-C91G did not
significantly enhance STING or IRF3 phosphorylation (Fig. 5A, lane 3).
UMRC6 cells expressing BAP1-WT, but not BAP1-C91G, also had higher
levels of phosphorylated IRF3, the active form of this transcription
factor, in the nuclear fraction of cell lysates (Fig. 5B). In Ren-02 cells,
BAP1 suppression reduced total STING protein levels (Fig. 5C). Further,
mRNA levels of STING1 were increased by BAP1-WT, but not BAP1C91G, in UMRC6 (Fig. 5D) and UMRC2 (Fig. 5E) cells and were
modestly reduced by BAP1 shRNAs in Ren-02 cells (Fig. 5F). These re
sults demonstrated a link between BAP1 and STING expression and ac
tivity in ccRCC cells.
To determine whether this connection was confined to ccRCC cells,
primary cells were obtained from the kidneys of WT and Bap1fl/fl mice
and protein expression was examined. A high percentage of these cells
were of epithelial origin, as determined by morphology and cytokeratin
8 immunohistochemistry (Data in Brief Fig. 5A and B). Adeno-Cre
treatment reduced BAP1 protein levels and led to a decrease in STING
in Bap1fl/fl cells but did not alter STING levels in WT cells (Fig. 5G). This
was observed in multiple pairs of cells from the Bap1fl/fl and WT mice
(Data in Brief Fig. 5C). This suggests that the connection between BAP1
and STING is conserved between mice and humans and is not limited to
cancer cells.
To further validate the hypothesis that BAP1 loss leads to reduced
STING expression in cancer cells, the association between BAP1 and
STING expression was assessed in patient samples using immunohisto
chemistry. A TMA was previously generated from 160 ccRCC patients
(40 per stage, ~4 foci per tumor), probed with various antibodies
against the targets of interest, and scored by pathologists. Because
ccRCC tumors contain many endothelial and immune cells that express
high levels of STING (Supplementary Figs. 2A–F), and these cells do not
have BAP1 mutations, their signals could distort the final correlation
analysis if the whole tissue was used. In fact, no correlation between
STING mRNA levels and BAP1 mRNA levels or BAP1 mutation status is

3.4. BAP1 enhances ISGF3 activity through IFN-β
Considering that the VHL-HIF axis regulates IFNB1 expression, which
is important for ISGF3 activity, we investigated whether BAP1 also
regulates IFN-β. In Ren-02 cells, suppression of BAP1 by shRNAs
(Fig. 4A) led to modest reductions in the transcript levels of IFNB1 but
did not affect IFNA (Fig. 4B and C). In UMRC6 cells, in which BAP1-WT
and BAP1-C91G were expressed to a similar extent (Fig. 4D), BAP1-WT
induced IFNB1 expression, whereas BAP1-C91G did not (Fig. 4E).
Neither BAP1-WT nor BAP1-C91G affected IFNA expression (Fig. 4F).
This suggests that BAP1 upregulates IFN-β expression in a DUB7
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Fig. 4. BAP1 enhances ISGF3 activity through IFN-β. (A–C) RT-qPCR measurement of the indicated transcripts in Ren-02 cells (n = 6) expressing SCR or BAP1
shRNAs. (D-F) RT-qPCR measurement of the indicated transcripts in UMRC6 cells (n = 3) expressing control (GFP), BAP1-WT, or BAP1-C91G constructs. (G-J) RTqPCR measurement of the indicated transcripts in UMRC6 cells (n = 6) expressing control (GFP) or BAP1 constructs and control (SCR) or IFNB1 shRNAs. †; p = 0.12.
(K) SDS-solubilized whole cell lysates of UMRC6 cells (n = 3) expressing GFP or BAP1 constructs and SCR or IFNB1 shRNAs and blotted with the indicated antibodies.
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Fig. 5. BAP1 stimulates ISGF3 activity through STING. (A) SDS-solubilized whole cell lysates of UMRC6 cells (n = 3) expressing control (GFP), BAP1-WT, or
BAP1-C91G constructs and blotted with the indicated antibodies. (B) Cytoplasmic and nuclear protein fractions extracted from UMRC6 cells (n = 3) expressing GFP,
BAP1-WT, or BAP1-C91G constructs and blotted with the indicated antibodies. (C) SDS-solubilized whole cell lysates of Ren-02 cells (n = 3) expressing control (SCR)
or BAP1 shRNAs and blotted with the indicated antibodies. (D) RT-qPCR measurement of STING1 transcripts in UMRC6 cells (n = 6) expressing control (GFP), BAP1WT, or BAP1-C91G constructs. (E) RT-qPCR measurement of STING1 transcripts in UMRC2 cells (n = 4) expressing control (GFP). BAP1-WT, or BAP1-C91G con
structs. (F) RT-qPCR measurement of STING1 transcripts in Ren-02 cells (n = 8) expressing control (SCR) or BAP1 shRNAs. (G) EBC-solubitized lysates of primary
fl
kidney cells from WT or Bap1fl/ mice (n = 3) treated with adenovirus-empty or -Cre and blotted with the indicated antibodies. (H) Odds ratio (OR) for association
between BAP1 IHC loss and STING IHC loss in the stroma and cancer cells. Analysis was performed for all samples and for samples within each tumor stage and grade.
Images below are STING and BAP1 IHC samples assigned the indicated staining intensity scores. (I) SDS-solubilized whole cell lysates of UMRC6 cells (n = 5)
expressing GFP, BAP1-WT. or BAP1-C91G treated with H-151 for 24 h and blotted with the indicated antibodies. +, 1 μM; ++, 5 μM.
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most subgroups, the only subgroup with a significant association was
stage 4 (OR, 3.2; 95% CI 1.6–6.6; p = 0.0011). In cancer cells, the
estimated odds ratio for the association of BAP1 IHC loss with STING
loss was 1.9 (95% CI 1.2–2.9; p = 0.0035) across all samples. Significant
associations were also observed for grade 3 and stage 4 subgroups (95%
CI 1.2–4.1; p = 0.0072; 95% CI 3.4–30.8, p < 0.0001, respectively). This

observed in the ccRCC TCGA dataset (Supplementary Figs. 2G–H).
Therefore, we analyzed STING expression in the cancer cells and stroma
separately and compared the data with those for BAP1 IHC loss. The
estimated odds ratio (OR) for the association of BAP1 IHC loss with
STING loss in the stroma was 1.6 (95% CI 1.0–2.5; p = 0.0693) across all
samples (Fig. 5H). Although the estimated ORs were greater than 1 in

Fig. 6. BAPI suppression of tumorigenesis was verified in a ccRCC xenograft model. (A) Images of athymic nude mice (n = 12) injected with Ren-02 cells
expressing control (SCR) or BAP1 shRNA, with xenografted tumors below. (B) Quantification of tumor weights. Tumors from individual mice are connected by a line.
The difference in tumor weights was calculated and compared using the two-tailed Student’s t-test. (C) EBC lysates were harvested from paired tumors in two mice
and blotted with the indicated antibodies. (D) H&E and IHC staining of tumor tissue from a representative mouse. (E) Graph of cell proliferation in the indicated Ren02 cell lines measured via XTT assay (n = 3). (F) Images of athymic nude mice (n = 10) injected with Ren-02 cells expressing BAP1 shRNA and control (GFP) or
BAP1* (shRNA-resistant BAP1), with xenografted tumors below. (G) Quantification of tumor weights. Tumors from individual mice are connected by a line. The
difference in tumor weights was calculated and compared using the two-tailed Student’s t-test. (H) EBC lysates were harvested from paired tumors in two mice and
blotted with the indicated antibodies. (I) H&E and IHC staining of tumor tissue from a representative mouse. (J) Graph of cell proliferation of the indicated Ren-02
cell lines measured via XTT assay (n = 3).
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suggests that the link between BAP1 and STING expression is also pre
sent in human ccRCC tumors and is primarily observed in cancer cells.
To determine the extent to which ISGF3 activation by BAP1 depends
on STING, UMRC6 cells expressing GFP, BAP1-WT, or BAP1-C91G were
treated with increasing doses of H-151, a STING antagonist. Inhibition of
STING had little effect on STING-TBK1-IRF3 phosphorylation or ISGF3
target expression in the control and BAP1-C91G-expressing cells (Fig. 5I,
lanes 1–3 and 7–9). However, reduced phosphorylation of STING, TBK1,
and IRF3, as well as reduced expression of MDA5, RIG-I, OAS1, and
PLSCR1, was observed in BAP1-WT-expressing cells treated with H-151
(Fig. 5I, lanes 4–6). Further, suppression of STING by shRNA reduced the
upregulation of ISGF3 target proteins by BAP1 in both Ren-02 and
UMRC6 BAP1-expressing cells (Data in Brief Fig. 6). Together, these
results show that BAP1 promotes the activation of the STING-IRF3
pathway, which is a major route to ISGF3 stimulation.

expressed in Ren-02 shBAP1-74 cells. Cells expressing BAP1* formed
significantly smaller tumors in mouse xenograft assays (Fig. 6F and G)
and maintained STING and ISGF3 pathway activation until the end of
the experiment (Fig. 6H). IHC analysis of tumor tissue showed no
changes in CD31 expression, but increased CD45 staining was observed
in some BAP1* tumors (Fig. 6I). No significant differences in prolifera
tion were observed between cells in vitro (Fig. 6J). This evidence sup
ports the role of BAP1 as a tumor suppressor in ccRCC.
3.7. Genetic activation of ISGF3 blocks tumor growth by BAP1-deficient
cancer cells
Next, we sought to determine the significance of ISGF3 regulation in
BAP1’s tumor suppressor function. Our results showed that IFN-β is
tumor-suppressive and BAP1 upregulates IFN-β; therefore, we hypoth
esized that genetic ISGF3 activation may mimic IFN-β upregulation.
Ren-02 control and BAP1 knockdown cells expressing GFP or IRF9 fused
to the C-terminal transcriptional activation domain of STAT2 (9-2C)
were generated. 9-2C overexpression significantly increased ISGF3
target abundance in both control and BAP1 knockdown cells (Fig. 7A).
Additionally, 9-2C overexpression decreased the growth of BAP1
knockdown cells relative to the control in xenograft assays (Fig. 7B and
C). 9-2C overexpressing cells exhibited reduced proliferation in vitro
(Fig. 7D). These results suggest that ISGF3 upregulation is a major
tumor-suppressing mechanism of BAP1 and that genetic activation of
ISGF3 suppresses the growth of BAP1-deficient tumors.

3.6. BAP1 suppression of tumorigenesis was verified in a ccRCC xenograft
model
Thus far, no xenograft models have been reported showing the tumor
suppressor function of BAP1 using ccRCC cells. To establish this model,
we manipulated BAP1 expression in Ren-02 cells and compared their
growth in vivo using xenograft assays. The same number of cells
expressing control or BAP1 shRNA were injected into the flanks of nude
mice. BAP1 knockdown cells formed significantly larger tumors in vivo
(Fig. 6A and B) and maintained suppression of the STING and ISGF3
pathways until the end of the experiment (Fig. 6C). IHC analysis of the
tumor tissue revealed no differences in Ki67, cleaved caspase 3, or CD31
staining (Fig. 6D), suggesting that BAP1 does not affect proliferation,
apoptosis, or blood vessels in this model. In some of the tumor pairs
analyzed, however, a trend of reduced CD45 staining, a marker of im
mune cells, was observed in the BAP1 knockdown tumors (Fig. 6D).
Minor increases in cell proliferation due to BAP1 suppression were
observed in vitro (Fig. 6E).
To confirm this observation, a BAP1 rescue experiment was per
formed in which GFP and shRNA-resistant BAP1 (BAP1*) were

3.8. A STING agonist increases ISGF3 activity and slows the growth of
BAP1-deficient tumors
Finally, we sought to determine the impact of the pharmacological
activation of ISGF3 in BAP1-deficient cells and tumors. Cells were
treated with diABZI, a STING agonist that promotes IFN production, as
well as IFN-β. Both diABZI and IFN-β treatment elevated ISGF3 target
expression in the Ren-02 control and BAP1 knockdown cells (Fig. 8A).
Notably, the effect of diABZI was more pronounced in the control cells
Fig. 7. Genetic activation of ISGF3 blocks tumor
growth by BAP1-deficient cancer cells. (A) SDSsolubilized whole cell lysates of Ren-02 cells (n = 4)
expressing SCR or BAP1 shRNA and GFP or IRF9STAT2C (9-2C) constructs and blotted with the indi
cated antibodies. For the IRF9 immunoblot, the first
row of quantification represents the IRF9-STAT2C
fusion protein, while the second row represents
endogenous IRF9. (B) Images of athymic nude mice
(n = 9) injected with Ren-02 cells expressing BAP1
shRNA and GFP or IRF9-STAT2C (9-2C), with xeno
grafted tumors below. (C) Quantification of tumor
weights. Tumors from individual mice are connected
by a line. The difference in tumor weights was
calculated and compared using the two-tailed Stu
dent’s t-test. (D) Graph of cell proliferation in the
indicated Ren-02 cell lines measured via XTT assay
(n = 3).
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Fig. 8. A STING agonist increases ISGF3 activity and slows the growth of BAP1-deficient tumors. (A) SDS-solubilized whole cell lysates of Ren-02 cells (n = 2)
expressing SCR or BAP1 shRNAs treated 24 h with 100 pg/ml IFN-β or diABZI (+, 1 μM; ++, 5 μM) and blotted with the indicated antibodies. (B) SDS-solubilized
whole cell lysates of UMRC6 cells (n = 3) expressing GFP or BAP1, treated 24 h with 1 μM diABZI, and blotted with the indicated antibodies. (C) Images of
representative athymic nude mice (n = 8 per treatment group) bearing Ren-02 shBAP1 tumors and treated twice-weekly with vehicle (control) or 3 mg/kg diABZI via
intraperitoneal route (left). Graph of individual Ren-02 shBAP1 tumor volumes relative to size at onset of treatment (right). (D) Relative tumor volume of all mice in
each treatment group (n = 8) measured twice weekly. (E) EBC lysates were harvested from tumors in four mice and blotted with the indicated antibodies. (F) H&E
and IHC staining of tumor tissue from representative mice.
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due to the higher inherent STING expression. In UMRC6 cells, diABZI
treatment increased ISGF3 target levels in cells expressing GFP or BAP1WT (Fig. 8B).
To test the effect of STING activation in vivo, mice bearing tumors
generated by Ren-02 shBAP1-74 cells were treated with vehicle or
diABZI via intraperitoneal injection, and the tumor volume was moni
tored over time. Treatment with diABZI significantly hindered BAP1
knockdown tumor growth over the course of treatment (Fig. 8C–E) and
promoted IRF3 phosphorylation and ISGF3 target activation in the
tumor lysates (Fig. 8F). IHC revealed no differences in CD31 staining,
but an increase in CD45 staining was observed in the diABZI-treated
tumors (Fig. 8G, Data in Brief Fig. 7). Collectively, these results sug
gest that STING activation may be an effective strategy for slowing the
growth of BAP1-deficient ccRCC tumors.

specific types of innate immune cells involved and the role of the
adaptive immune system in this context warrant further investigation.
Previous studies in uveal melanoma (UM) and PeM have found as
sociations between reduced BAP1 expression and increased T cell infil
tration in patient tumor samples [47–50]. BAP1-deficient tumors have
been reported to exhibit increased expression of genes involved in im
mune exhaustion [47], immune evasion [48], T cell chemoattraction
[49], and the NF-κB pathway [50]. Additionally, BAP1 mutations have
been associated with an increased presence of immunosuppressive reg
ulatory T cells in ccRCC tumors [55]. However, details of the molecular
mechanism(s) by which BAP1 regulates the TIME are lacking. ccRCC has
a high immune infiltrate [56], which can be exploited therapeutically
using immune checkpoint inhibitors. In this study, we observed that
BAP1-deficient ccRCC cells exhibited reduced type I IFN signaling,
which may result in lower levels of DC activation, T effector cell
recruitment, and T cell-mediated cytotoxicity. If this is found to be the
case in BAP1-deficient ccRCC patients, it will be important to consider
how to best modulate the TIME to promote the antitumor immune
response.
As there are currently no treatments specific for BAP1-deficient
cancers, we hypothesize that ccRCC patients with loss of BAP1 func
tion may benefit from treatment with an ISGF3 activator. In the absence
of BAP1, ccRCC tumors may become accustomed to low expression of
STING and IFN-β and minimal ISGF3 function. Such tumors may
therefore be uniquely sensitive to ISGF3 stimulation and the resulting
modulation of the TIME. Various clinical trials are ongoing or upcoming
that will investigate the use of STING agonists E7766, TAK-500, TAK676, SNX281, GSK3745417, and KL340399 in solid tumors
(NCT04144140, NCT05070247, NCT04420884, NCT04609579,
NCT03843359, and NCT05387928 respectively). We have provided
evidence that the preclinical STING agonist diABZI, a stable non-cyclic
dinucleotide compound with antitumor activity in an immunocompe
tent mouse model of colon cancer [57], upregulates ISGF3 activity and
hinders the growth of BAP1-suppressed ccRCC cells in vivo. Thus, STING
activation may be a novel therapeutic strategy for treating
BAP1-deficient ccRCC.
In conclusion, we demonstrated that BAP1 loss reduces the activity of
the tumor-suppressive ISGF3 pathway in ccRCC cells by downregulating
STING and IFN-β. Reactivation of ISGF3, either genetically or pharma
cologically, can slow the growth of BAP1-deficient xenografts and may
serve as a novel therapeutic strategy for patients with BAP1-mutant
ccRCC.

4. Discussion
In this report, we provide evidence for novel functions of VHL,
HIF2α, and BAP1 in regulating type I IFN signaling in ccRCC. We showed
that HIF2α promotes ISGF3 activation and expression of the type I IFN
signature through IFN-β induction and that BAP1 is required to maintain
IFN-β expression. Additionally, we established a role for IFN-β in the
suppression of ccRCC tumor growth. Finally, we showed that BAP1mediated activation of the ISGF3 pathway is STING-dependent and
demonstrated that STING activation slows the growth of BAP1-deficient
ccRCC tumors in mice. The connection between BAP1 and STING was
confirmed in human ccRCC tumor samples and conserved in normal
primary mouse kidney cells. This work builds on our previous findings
implicating ISGF3, a central transcription factor in the type I IFN
pathway, as a key tumor suppressor in ccRCC [51] and illustrates the
mechanism by which certain major cancer genes regulate this pathway
to modulate tumor growth.
In the canonical cGAS-STING pathway, the presence of abnormal
nucleic acids in the cytoplasm causes STING to bind TBK1 and induce
TBK1 autophosphorylation. This promotes the phosphorylation of both
STING and IRF3 and leads to the production of type I IFN. Here, we
showed that in VHL− /− cells, both VHL re-expression and HIF2α sup
pression reduce IFN-β levels. Thus, our data suggest that type I IFN
regulation is a HIF-dependent effect of VHL loss. The mechanism by
which HIF2α promotes IFN-β expression and whether the STING-TBK1IRF3 axis is involved will be the subject of future studies.
In this study, we found that BAP1 enhanced the type I IFN signature
by upregulating STING-IRF3 signaling, leading to IFN-β production and
subsequent ISGF3 activation. We showed that in ccRCC patient samples,
BAP1 loss is closely associated with STING loss in cancer cells. Inter
estingly, another group found that BAP1 loss is associated with reduced
STING expression in a small cohort of patients with malignant peritoneal
mesothelioma (PeM) [48]. Future work should evaluate whether BAP1’s
regulation of STING and the IFN pathway is found in other cell types and
BAP1-associated cancers. At present, the molecular mechanism by
which BAP1 increases STING expression remains unknown, and further
research is needed.
Regulation of the type I IFN pathway by BAP1 may affect the tumor
immune microenvironment (TIME) of ccRCC and other BAP1-associated
cancers. We demonstrated that both genetic and pharmacological acti
vation of the ISGF3 pathway reduced the growth of BAP1-deficient tu
mors in mouse xenografts. Type I IFN exerts both tumor cellautonomous effects, including reduction of proliferation and enhance
ment of apoptosis, and immune cell-dependent effects on cancer growth,
including activation of dendritic cells (DCs) and CD8+ cytotoxic T cells
[53]. As the nude mice used in our study lacked an adaptive immune
system, our results suggest that ISGF3 activation affects the cancer cells
and/or cells of the host innate immune system, such as macrophages or
natural killer cells. Future studies stemming from this work will need to
use immunocompetent mouse models to examine the mechanisms of
tumor suppression by BAP1 and the type I IFN pathway in ccRCC. The
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